Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 6, 2013
Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the...
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 22, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
-
Nov 21, 2013
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable MicrocatheterProprietary Shaft Design Enables Better Control In Hard-To-Navigate Vessels
Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
-
Nov 19, 2013First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease
The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment...
-
Nov 15, 2013Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the...
-
Nov 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Nov 1, 2013
Boston Scientific Corporation (NYSE:BSX) today closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of...
-
Oct 31, 2013New Data Announced At TCT 2013 Demonstrate Successful Deployment In All 120 Patients With No Severe Paravalvular Regurgitation At 30 Days
The Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System met a key performance measure in the treatment of symptomatic patients with...
-
Oct 31, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Credit Suisse Healthcare Conference on November 12 in Scottsdale,...
-
Oct 28, 2013REDUCE-HTN Data Presented Today at TCT Demonstrate Excellent Safety Profile
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood...
-
Oct 28, 2013
Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...
-
Oct 28, 2013Transcatheter Aortic Valve Replacement (TAVR) Device Offers Precise Positioning and Placement, Offering Physicians Unprecedented Control
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Lotus™ Valve System, the company's advanced transcatheter aortic valve...
-
Oct 24, 2013Jeffrey Capello to Transition Out of CFO Role at Year-End
Boston Scientific Corporation (NYSE: BSX) has initiated a transition plan for its new chief financial officer. Noting a desire to pursue opportunities...
-
Oct 24, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.17 for the third quarter ended...
Oct 23, 2013Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbationsBoston Scientific Corporation (NYSE: BSX) has received China Food and Drug Administration approval for the Alair® Bronchial Thermoplasty System, an...
-
Oct 23, 2013Award Recognizes Innovative S-ICD® System, the World's First and Only Subcutaneous Implantable Defibrillator
The Boston Scientific Corporation (NYSE: BSX) S-ICD® System has received the Prix Galien USA 2013 Award for Best Medical Technology. The S-ICD...
-
Oct 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2013 on
-
Oct 9, 2013MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions
Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are...
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
-
Sep 17, 2013
ORBUSNEICH, BOSTON SCIENTIFIC SETTLE PATENT LITIGATION Fort Lauderdale, Fla. and Natick, Mass. (September 17, 2013) -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have...
-
Sep 17, 2013
Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
Sep 17, 2013REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves CourseBOSTON SCIENTIFIC REPORTS favorable SIX-MONTH RESULTS from LOTUS™ valve system clinical trial REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Natick, Mass. (Sept. 17,...